Literature DB >> 17544120

Clinical spectrum of gammadelta+ T cell LGL leukemia: analysis of 20 cases.

A S Bourgault-Rouxel1, T P Loughran, R Zambello, P K Epling-Burnette, G Semenzato, J Donadieu, L Amiot, T Fest, T Lamy.   

Abstract

We report on the clinico-biological characteristics of 20 cases of gammadelta T cell large granular lymphocyte (LGL) leukemia. All the data were compared to that of 196 cases with alphabeta T cell subtype, which represents the majority of T cell LGL leukemias. Clinical findings were quite similar in the two groups regarding age, sex ratio, recurrent infections, and association with auto-immune diseases especially rheumatoid arthritis. Gammadelta LGL predominantly expressed a CD3+/CD4-/CD8+/CD16+/CD57+ phenotype, in 50% of cases. Clinical outcome was favorable for these patients with overall survival of 85% at 3 years. Fifty percent of gammadelta patients required treatment and the response to therapy was estimated at 55%. gammadelta and alphabeta T cell LGL leukemia harbor a very similar clinico-biological behavior and represent part of an antigen-driven T cell lymphoproliferation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17544120     DOI: 10.1016/j.leukres.2007.04.011

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  17 in total

1.  Large granular lymphocyte disorders: new etiopathogenetic clues as a rationale for innovative therapeutic approaches.

Authors:  Renato Zambello; Gianpietro Semenzato
Journal:  Haematologica       Date:  2009-10       Impact factor: 9.941

2.  CD103+ γδ T cell large granular lymphocytosis in a patient with refractory celiac disease: a diagnostic enigma.

Authors:  Sreejesh Sreedharanunni; Neelam Varma; Man Updesh Singh Sachdeva; Kirti Gupta; Rekha Pai; Rakesh Kochhar; Pankaj Malhotra; Subhash Varma
Journal:  Int J Hematol       Date:  2015-01-31       Impact factor: 2.490

Review 3.  The pathogenesis and treatment of large granular lymphocyte leukemia.

Authors:  Steven Nathaniel Steinway; Francis LeBlanc; Thomas P Loughran
Journal:  Blood Rev       Date:  2014-03-07       Impact factor: 8.250

4.  How I treat LGL leukemia.

Authors:  Thierry Lamy; Thomas P Loughran
Journal:  Blood       Date:  2010-12-29       Impact factor: 22.113

5.  Defining TCRγδ lymphoproliferative disorders by combined immunophenotypic and molecular evaluation.

Authors:  Antonella Teramo; Andrea Binatti; Elena Ciabatti; Gianluca Schiavoni; Giulia Tarrini; Gregorio Barilà; Giulia Calabretto; Cristina Vicenzetto; Vanessa Rebecca Gasparini; Monica Facco; Iacopo Petrini; Roberto Grossi; Nadia Pisanti; Stefania Bortoluzzi; Brunangelo Falini; Enrico Tiacci; Sara Galimberti; Gianpietro Semenzato; Renato Zambello
Journal:  Nat Commun       Date:  2022-06-08       Impact factor: 17.694

6.  The gammadelta variant of T cell large granular lymphocyte leukemia is very similar to the common alphabeta type: report of two cases.

Authors:  Gene R Shaw; Vinay S Naik
Journal:  J Hematop       Date:  2008-08-23       Impact factor: 0.196

Review 7.  The root of many evils: indolent large granular lymphocyte leukaemia and associated disorders.

Authors:  Ranran Zhang; Mithun Vinod Shah; Thomas P Loughran
Journal:  Hematol Oncol       Date:  2010-09       Impact factor: 5.271

8.  Persistent γδ T large granular lymphocytosis in a patient with refractory pure red cell aplasia, celiac disease, and chronic hepatitis B infection.

Authors:  S Sreedharanunni; Mus Sachdeva; G Prakash; R Das
Journal:  J Postgrad Med       Date:  2016 Jan-Mar       Impact factor: 1.476

Review 9.  Metronomic regimen as an effective treatment for aggressive T-LGL leukemia with central nervous system infiltration: clinical experience and review of literature.

Authors:  Yun Liu; Lei Fan; Huihui Zhao; Wei Xu; Jianyong Li
Journal:  Oncotarget       Date:  2017-05-09

10.  Are T-LGL Leukemia and NK-Chronic Lymphoproliferative Disorder really two distinct diseases?

Authors:  Renato Zambello; Antonella Teramo; Cristina Gattazzo; Gianpietro Semenzato
Journal:  Transl Med UniSa       Date:  2014-02-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.